Telix at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

Telix is sponsoring a symposium and presenting the company’s prostate cancer imaging agent and clinical programs at #SNMMI22, being held in Vancouver, Canada from 11-14 June, 2022. 

9 June 2022 – Corporate Spotlight | Telix announces presence at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

Telix is sponsoring a symposium and presenting the company’s prostate cancer imaging agent and clinical programs at #SNMMI22, being held in Vancouver, Canada from 11-14 June, 2022.

?  SPONSORED SYMPOSIUM, Monday, 13 June, 11:45 am – 12:45 pm PDT (4.45 am – 5:45 am AEST)

➖ PSMA: the next frontier in Theranostics – transforming PCa care. Don’t get left behind… 

  • Join a renowned panel of Nuclear Medicine thought leaders moderated by Dr. Delphine Chen, Professor of Radiology, Director of Molecular Imaging, Seattle Cancer Care Alliance, University of Washington to explore how the introduction of PSMA-PET has changed the landscape of Prostate Cancer Management including extensive Case Review.

?  ORAL PRESENTATION, Sunday June 12, 1:10 pm – 1:20 pm PDT (6:10 am – 6:20 am AEST)

➖ 18F-Fluciclovine and 68Ga-PSMA-11 PET/CT for Detection of Invasive Lobular Breast Cancer: Interim Report from an Exploratory Trial .

  • Dr. David Schuster from Emory University presents on the use of  68Ga-PSMA-11 PET/CT for Detection of Invasive Lobular Breast Cancer. Invasive lobular breast cancer (ILC) has a distinct histology and discohesive growth which makes it difficult to visualize with conventional imaging (CI), including FDG PET. Prostate specific membrane antigen (PSMA) PET is under study to detect ILC due to the upregulation of PSMA receptors in tumor angiogenesis. Telix is proud to be supporting this important independent initiated trial.

?  POSTER SESSION, Saturday, 11 June, 6:00 pm – 8:00 pm PDT

➖ Added diagnostic confidence of identifying prostate cancer metastases with Ga-68 PSMA-11 PET.

  • Data being presented by Dr. Delphine Chen and colleagues at the Seattle Cancer Care Alliance evaluating how PSMA-11 PET can potentially determine the presence or absence of prostate cancer in equivocal lesions by conventional imaging and consequently change of management. Telix is proud to be supporting this important independent initiated trial.

The full program can be found on the SNMMI website: https://am.snmmi.org/imis/SNMMI-AM/Program/SNMMI-AM/Agenda.aspx

Still time to register here: https://am.snmmi.org/iMIS/SNMMI-AM/RegistrationOnline.aspx